An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2018
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 23 Aug 2018 The status of the trial has been changed to discontinued.
- 22 Sep 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2018.